Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Folqs, a U.S.-based wellness company, introduces new consumer product, ...

Importantly, these exosomes were produced from NurExone’s proprietary master cell bank, whose cells are maintained under ...

Aja Health and Wellness Inc. ("Aja" or the "Company") (TSXV:Aja) announces that the Alberta Securities Commission (the "ASC"), as its principal regulator, has revoked the management cease trade order ...

Singapore, Singapore, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Heartland Physio is proud to unveil its signature R.E.A.L. Recovery™ ...

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout ...

WARREN, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced an update on institutional ownership of the Company’s outstanding ...

The test, based on immunochromatographic technology, enables reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole blood. This addition strengthens Anbio’s ...

Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock ...

Noble Capital Markets, Inc. acting as the sole placement agent in connection with the offering. The gross proceeds to the Company are expected to be approximately $20 million before deducting the ...

About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...

Genio is a different approach to hypoglossal nerve stimulation (HGNS) for the treatment of OSA. Genio’s unique design utilizes bilateral stimulation, and offers patients a leadless, full-body 1.5T and ...

This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of ...